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Abstract
Chronic kidney disease (CKD), a major public health problem that affects up to 10–13% 
of the general population worldwide, imposes considerable socio-economic burden due 
to both the need for renal replacement therapy and, even more important, the negative 
influence on the overall patients’ health status. Cardiovascular (CV) diseases are the main 
cause of death in CKD patients and are triggered not only by the traditional CV risk 
factors but also by specific, uremia-related, factors. Among these, calcium-phosphate 
and bone metabolism disorders play a central role. Abnormalities of mineral metabo-
lism occur early, evolve silently as the kidney function deteriorates, and are associated 
with CV morbidity and mortality, mainly by the development of valvular and vascular 
calcifications. This chapter aims to summarize the recent knowledge on the types and 
mechanisms of arterial calcifications, as well as their clinical implications, in the setting 
of CKD. The issue is significant for both nephrologists and cardiologists and could be an 
example of the requirement for interdisciplinary collaboration in the medical practice.
Keywords: atherosclerosis and arteriosclerosis, arterial stiffness, calcifications, 
cardiovascular morbidity, chronic kidney disease
1. Introduction
The prevalence of chronic kidney disease (CKD) is constantly growing [1] largely due to the 
shift in age distribution of the population toward individuals older than 60 years, in which 
CKD is more common, accounted for by the combined effect of physiologic decline in glomer-
ular filtration rate (GFR) and systemic atherosclerosis, and also due to increasing prevalence 
of arterial hypertension, diabetes mellitus, and obesity, all risk factors for CKD. Notably, the 
mortality of CKD patients is higher than their non-CKD counterparts, predominantly with 
respect to cardiovascular mortality. Abnormalities of arterial and left ventricular functions, 
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such as arterial stiffness, atherosclerosis and arteriosclerosis, left ventricular hypertrophy, and 
systolic and end-diastolic stiffness, which are common in CKD patients, were incriminated 
[2]. The pathophysiology of cardiovascular disease (CVD) in CKD is complex, with both tra-
ditional and uremia-related risk factors being involved. Among the latter, calcium-phosphate 
metabolism anomalies are more and more debated, and the concept of chronic kidney disease-
mineral and bone disorder (CKD-MBD) has been adopted. It is a broad term that refers to a 
systemic disorder of mineral metabolism due to the kidneys’ failure to maintain homeostasis 
of calcium (Ca), phosphate (PO
4
), and active vitamin D, which leads to maladaptive altera-
tions in related hormones, namely fibroblast growth factor-23 (FGF23) and parathyroid hor-
mone (PTH), and results in defective bone architecture and extraskeletal calcifications [3, 4]. 
CKD-MBD occurs early in the course of CKD, progresses as kidney function declines, and it 
is manifested by three separate, but interrelated, components that are not necessarily present 
concurrently in all patients, any combination of these component being possible [4]:
1. Changes in biochemistry profile (Ca, PO
4
, vitamin D, PTH, FGF23, and alkaline phos-
phatase—ALP), which reflect mineral and hormonal abnormalities;
2. Bone abnormalities regarding turnover, mineralization, volume, linear growth, or strength; 
and
3. Soft tissue (vascular, valvular, and periarticular) calcifications.
The vascular calcifications at least partially account for increased cardiovascular (CV) risk in 
CKD patients, so it is worth to draw attention on the mechanisms involved in their development.
2. Types and characteristics of vascular calcification in chronic 
kidney disease
Even at early ages, CKD patients develop vascular calcifications at all the levels (large vessel 
arteries such as the aorta, medium arteries like the coronary arteries, as well as small-caliber 
arteries of the skin), in a much greater proportion than the general population, and the preva-
lence and severity of arterial and valvular calcifications increase as kidney function decreases [5].
The main types of arterial calcifications, both commonly seen in CKD, are distinguished by 
their location in the structure of the arterial wall (Figure 1) and their association with athero-
sclerotic plaque formation:
1. Atherosclerosis consists in the calcification of the intimal layer in association with cellular necro-
sis, inflammation, atherosclerotic plaques, and lipid deposition [6]. This type of calcification 
is related to traditional risk factors such as arterial hypertension and dyslipidemia (Table 1). 
The vessel lumen is eccentrically reduced and deformed due to patchy calcification of the 
atherosclerotic plaques [7]. It produces arterial stenosis which accounts for tissular ischemia 
and infarction and may predispose to plaque rupture generating life-threatening thrombi.
2. Arteriosclerosis, which represents the calcification of the medial layer, occurs in the elastic 
lamina of large-caliber and medium- to small-size arteries. It seems to be independent of 
atherosclerosis, although both can coexist [6, 7]. Medial calcification was known initially as 
Chronic Kidney Disease - from Pathophysiology to Clinical Improvements62
Mönckeberg’s sclerosis, and it has radiographically been described as “railroad tracks” on 
the peripheral arteries of upper and lower limbs [6, 8]. This type of calcification is related 
to non-traditional risk factors such as hyperphosphatemia, excess PTH, and cytokines of 
chronic inflammation (Table 1), and it is more prevalent in patients with CKD and diabe-
tes [6]. The vessel lumen is reduced concentrically due to amorphous mineral that forms 
circumferentially along or within one or more elastic lamellae of the media [7]. It induces 
arterial stiffness, which contributes to increased pulse pressure and, consequently, to left 
ventricular hypertrophy and altered coronary perfusion [9, 10].
Figure 1. Main types of arterial calcifications and their consequences. VSMCs, vascular smooth muscle cells.
Traditional risk factors Non-traditional (CKD-related) risk factors
Arterial hypertension Hyperphosphatemia, high calcium-phosphate product
Dyslipidemia Hyper- or hypoparathyroidism
Diabetes mellitus High dosage of vitamin D metabolites
Smoking Chronic inflammation
Old age Oxidative stress
Family history of premature coronary heart  
disease
Metabolic abnormalities: hypoalbuminemia, hyperhomocysteinemia
Decrease of calcification inhibitors (Fetuin-A)
Anemia
CKD: chronic kidney disease.
Table 1. Risk factors for vascular calcification in chronic kidney disease patients (modified from Román-García et al. [5]).
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These two types of calcifications encountered in CKD also vary based on their localization on 
the arterial tree. Intimal calcifications are found more proximally, while medial ones have a 
predilection for distal sites [10].
Etiologically, vascular calcifications may be categorized as metastatic calcifications, those 
which arise from systemically high calcium and phosphate product, or dystrophic calcifica-
tions, which take place under pathologic conditions of cell death or apoptosis [9]. Metastatic 
calcifications occur when the calcium-phosphate product exceeds its solubility in serum result-
ing in its deposition in healthy, extraskeletal tissue such as the arterial wall, the viscera, the 
conjunctiva, articulations, or tumors [8]. In contrast, dystrophic calcifications result from the de 
novo deposition of calcium and phosphate in diseased or damaged tissue. This occurs when 
cells die as a result of direct injury or apoptosis and release their intracellular calcium contents 
which can serve as a foundation for further calcium deposition [8].
3. Pathogenesis of vascular calcifications in chronic kidney disease
3.1. Overview on the molecular basis of mineralization and vascular calcifications
Although not yet entirely elucidated, the process of vascular calcification was extensively 
studied and the bulk of its steps were unveiled. The common feature to almost all physiologic 
mineralization mechanisms, either inside the bone or in extra-osseous tissues, involves matrix 
vesicles, which form the nidus for hydroxyapatite crystals nucleation [11]. These matrix ves-
icles are membrane-bound particles of 20–200 nm where mineral crystals are arranged by 
interaction with specific regulators, like membrane transporters and enzymes, with crucial 
roles in the influx of calcium and phosphate ions into the vesicles [9]. For example, tissue 
nonspecific alkaline phosphatase hydrolyzes pyrophosphate and generates inorganic phos-
phate, which is further transported through the vesicle membrane by the sodium-phosphate 
cotransporter type III [12]. On the other hand, annexins function as ion channels and provide 
a way for calcium to enter inside the matrix vesicle, where the accumulation of both divalent 
ions induces crystalline nucleation [9, 12].
In the bone, matrix vesicles bud off from the plasma membrane of chondrocytes or osteo-
blasts, at the epiphyseal plate of growing bone and are released into the premineralized 
organic matrix where they serve as a vehicle for the interaction of calcium and phosphate 
ions to form hydroxyapatite and initiate mineralization of the organic substance [11]. 
Hydroxyapatite crystals that are released from vesicles serve as templates for subsequent 
crystal formation, creating the lattice of the bone [9, 13]. Therefore, matrix vesicles have an 
osteogenic role.
Growing body of evidence supports significant resemblance between bone and vascular cal-
cifications, leading to the belief that ectopic calcifications and normal osteogenesis are driven 
alike. Indeed, many cellular and molecular signaling processes are identical in vascular calcifi-
cation and osteogenesis. Among these, matrix vesicle release and expression of mineralization-
regulating proteins by vascular smooth muscle cells (VSMCs) are seen in the vessel wall [14]. 
Consequently, vascular calcification is also considered a regulated biomineralization process.
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The balance among promoters and inhibitors of calcification plays the key role during miner-
alization (Figure 2).
The main known inhibitor molecules involved in both bone and extra-osseous sites calcifica-
tion, are:
1. Matrix GLA protein (MGP, matrix γ-carboxyglutamate protein), an extracellular protein 
has roles in normal bone formation as well as inhibition of vascular calcification [15, 16]. 
The inactive MGP (desphospho-uncarboxylated MGP, dp-ucMGP) needs two subsequent 
modifications (serine phosphorylation and glutamate carboxylation) in order to exert its 
function [17]. Circulating levels of dp-uc MGP are considered a biomarker associated with 
cardiovascular risk and mortality, severity of the vascular damage, and all-cause mortality 
[17]. MGP is able to bind calcium and hydroxyapatite, thanks to its vitamin K-dependent 
γ-carboxylation, inhibiting their precipitation and mineralization [16]. MGP synthesis 
has been detected in cartilage, lung, heart, kidney, arteries, and calcified atherosclerotic 
plaques attesting to MGP’s role in inhibition of soft tissue calcifications [18]. In addition, 
recent works suggested a link between MGP and renal microvasculature, and argued in 
favor of a possible renoprotective action of activated MGP and, consequently, emphasized 
the importance of having adequate vitamin K stores [17].
2. Osteoprotegerin (OPG) is a soluble cytokine and tumor necrosis factor (TNF) receptor-like 
molecule that acts as an inhibitor of osteoclast differentiation by binding the receptor ac-
tivator of nuclear factor κB-ligand (RANKL), thus blocking RANKL-mediated activation 
of osteoclasts [11, 19]. OPG is present in many human tissues: bone (osteoblasts), vessels 
(endothelial and vascular smooth muscle cells), lung, heart, liver, kidney, hypothalamus, 
lymphoid organs and B-cells, bone marrow, articular chondrocytes, and breasts [19, 20]. 
Its expression in bone is regulated by osteoblasts through the same pathway that regulates 
bone formation, indicating RANKL/OPG ratio is a major determinant of bone mass and 
OPG has an osteoprotective role [21]. However, its functions in the vascular system are 
still a matter of debate. While experimental studies sustain an anti-calcification role (due to 
Figure 2. Regulating molecules of the mineralization/calcification processes. RANKL, receptor activator of nuclear 
factor-kB ligand; (+), stimulation; (−), inhibition.
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inhibition of apoptotic passive calcification and the alkaline phosphatase-mediated osteo-
genic differentiation of vascular cells), elevated serum levels of OPG were found in various 
cardiovascular diseases and were hypothesized as a promoter of atherosclerosis progres-
sion [19]. Osteoprotegerin expression was significantly lower and RANKL was identified 
in calcified valves of human aortic stenosis, indicating that in the absence of inhibition by 
OPG, RANKL may promote matrix calcification and induce the expression of osteoblast-
associated genes (bone alkaline phosphatase and osteocalcin) [22].
3. Extracellular pyrophosphate (PPi) is a small molecule made of two phosphate ions linked by 
an ester bond, which regulates cell differentiation and serves as an essential physiologic in-
hibitor of calcification by negatively interfering with hydroxyapatite formation and crystal 
growth [11]. PPi is produced from the hydrolyses of extracellular adenosine-5′-triphosphate 
by the enzyme ectonucleotide pyrophosphatase/phosphodiesterase [23]. On the other hand, 
alkaline phosphatase (ALP) catalyzes the hydrolysis of phospho-monoesters (including 
PPi) with release of inorganic phosphate (P
i
) in order to avoid accumulation of this miner-
alization inhibitor, thus ensuring normal bone mineralization [11, 24]. However, through 
this action, ALP also acts as a powerful inducer of vascular calcification partially as a result 
of increased PPi degradation [23].
4. Fetuin-A, a circulating glycoprotein from the cystatin superfamily of proteins, produced 
by the liver, functions as a potent inhibitor of de novo hydroxyapatite formation from 
supersaturated mineral solutions, and it also acts as a negative acute phase reactant, thus 
being downregulated in acute and chronic systemic inflammation [25–27]. In experimental 
and clinical studies, it was shown that serum containing fetuin-A inhibited precipitation 
of calcium salts in a dose-dependent manner, and its serum concentrations were inversely 
correlated to C-reactive protein, calcifications, and cardiovascular and all-cause mortality, 
even when the serum calcium-phosphate product was close to the normal range [26, 28]. 
Hence, it was assumed that a major link between low fetuin-A levels and mortality consists 
of promoting accelerated cardiovascular calcification [26].
Other main factors with essential contribution to the processes of mineralization and calcifica-
tion are those involved in the signaling pathways, like:
1. Bone morphogenetic proteins (BMPs) are cytokines with multiple functions, which modulate 
gene expression through phosphorylation of regulatory Smad transcription factors [16, 
27]. Smad6 and Smad7 proteins act as negative regulators and thus are crucial to limit 
the osteogenic vascular response induced by BMPs [27]. For example, BMP 2—a protein 
that belongs to the transforming growth factor-β (TGF-β) superfamily of cell regulatory 
proteins—is involved in both osteogenic and chondrogenic differentiation of multipotent 
mesenchymal progenitors and drives the formation of cartilage and bone [29]. It also par-
ticipates in vascular calcification probably through inducing osteoblastic differentiation of 
VSMCs. Conversely, BMP 7, primarily expressed in the kidney where it is required for the 
normal development of the organ, was found to restore the bone anabolic balance, reduce 
serum phosphate levels, and reduce vascular calcification [27].
2. Core-binding factor alpha 1 (Cbfa1), also known as runt-related transcription factor 2 (Runx2), 
is a nuclear protein essential for osteoblastic development and skeletal morphogenesis, and it 
is believed to be the switch that turns a mesenchymal cell into an osteoblast [11, 13, 30]. It acts 
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as a scaffold for the interaction of nucleic acids and regulatory factors that are involved in 
the expression of a number of downstream proteins essential for osteoblastic differentiation, 
such as type I collagen, osteocalcin, and osteopontin [13].
3. Type I collagen makes up over 90% of the organic component of bone where it forms the 
framework necessary for mineralization [13, 31]. It was shown that ex vivo cells grown on 
type I collagen were found to mineralize three times faster and incorporate two times more 
calcium than cells grown in plastic media. Moreover, rapidly mineralizing cells generate 
a matrix that contains three times the amount of collagen type I and fibronectin but 70% 
less collagen type IV than their non-mineralizing counterparts. These findings indicate a 
regulatory role of the matrix composition on arterial calcification development [31].
4. Osteocalcin is a protein secreted by active osteoblasts into the extracellular matrix where it 
binds hydroxyapatite via 3 γ-carboxylated glutamic acid residues during bone mineraliza-
tion. For this reason, it is often used as a marker for bone formation [32].
5. Osteopontin, also known as secreted phosphoprotein 1 or bone sialoprotein 1, is an ex-
tracellular structural component of bone (of the non-collagenous organic bone matrix) 
and an important modulator of bone mineralization, which can either promote or inhibit 
hydroxyapatite formation, depending on its post-translational modifications [11, 15]. 
Non-phosphorylated osteopontin shows a stimulatory effect on calcification, while phos-
phorylation of osteopontin converts it into a potent inhibitor of ectopic calcifications, pro-
portional to the number of phosphorylated sites [33]. Overexpression of osteopontin was 
found in human atherosclerotic plaques, in calcified smooth muscle cells, in medial layers 
of arteries of diabetic patient, and calcified heart valves, suggesting it intervenes in the 
development of ectopic calcifications [34].
In conclusion, mineralization and calcification processes are tightly regulated through the com-
plex interactions of various tissular and circulating molecules, many of which suffer profound 
changes in chronic kidney disease.
3.2. How does chronic kidney disease favor vascular calcifications?
3.2.1. Imbalance between pro- and counter-calcification factors
Vascular calcifications in CKD patients are thought to arise due to disruptions in the balance 
between promoters and inhibitors of calcification, leading to osteoblastic transformation of 
vascular smooth muscle cells (VSMCs) [5, 35]. Because VSMCs and osteoblasts derive from a 
similar mesenchymal cell precursor, VSMCs can be induced to differentiate along osteoblas-
tic lines. The process involves an increase in calcification promoters, decrease in calcification 
inhibitors, and formation of calcification vesicles culminating with the induction of a cellular 
phenotypic change from VSMCs to osteoblast-like cells [5].
Concerning promoters of calcification, it is recognized that the osteoblastic differentiation, which 
is the initial step in vascular calcification, is revealed by the expression of pro-calcification 
factors such as Cbfa1 and BMP on vascular cells [13, 15]. In vitro experiments showed that 
changes in serum composition like those that occurred in the course of CKD may upregu-
late expression of Cbfa1, while in vivo studies found higher expression of Cbfa1 in both the 
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media and intima of calcified arteries compared to non-calcified arteries of the same patients, 
thus emphasizing the important role of Cbfa1 in vascular calcifications [5, 36]. In addition, 
since positive immunostaining for bone matrix proteins (like osteonectin, osteopontin, bone 
sialoprotein, alkaline phosphatase, and type I collagen) were more common than overt calci-
fications but were proportional with their extent, it appears that the deposition of these pro-
teins precedes calcification [36]. Another modulator of calcification—osteocalcin—has been 
detected in VSMCs where it may potentially regulate their glucose utilization, promoting a 
phenotypic change in these cells [32]. Furthermore, an inverse correlation between osteopon-
tin plasma levels and glomerular filtration rate (GFR) was reported, suggesting that reduced 
renal excretion due to impaired kidney function may lead to increased circulating levels [37]. 
Increased osteopontin and other promoters of calcification in CKD can be accounted for by 
different mechanisms also. For example, in experimental settings, high concentrations of phos-
phorus, uremic serum, oxidized lipids, cytokines, and high glucose (abnormalities commonly 
seen in CKD patients as well) were able to stimulate the VSMCs and vascular pericytes to pro-
duce bone-forming transcription factors and proteins [36]. Taken together, these findings sug-
gest that biochemical changes that occur during the progression of CKD (hyperphosphatemia, 
hypercalcemia, accumulating uremic toxins, cytokines, oxidized lipoproteins, and advanced 
glycation end products) tip the balance in favor of promoters of vascular calcification.
On the other hand, abnormalities of calcification inhibitors can also contribute to the pathogen-
esis of vascular calcifications in CKD. For example, lower levels of matrix Gla protein were 
associated with decreased kidney function, probably because metabolic abnormalities due 
to CKD, such as vitamin D deficiency, may suppress MGP production. Alternatively, MGP 
may be lost from circulation as it binds to hydroxyapatite crystals in vascular calcifications. 
Regardless of the mechanism, reduced plasma MGP has been suggested as a marker for the 
presence and severity of vascular calcifications in patients with CKD [38]. Also, lower levels 
of circulating fetuin-A were described in CKD and were associated with coronary artery cal-
cification, valvular calcifications, and increased mortality in dialysis patients [36].
These changes in the levels of both promoters and inhibitors of vascular calcification, that occur 
in CKD patients, ultimately culminate in the transdifferentiation of VSMCs to an osteoblast phenotype 
through an active, cell-mediated, osteogenic process, with the release of calcium matrix vesicles 
that can nucleate hydroxyapatite and form the first nidus for calcification [11, 30]. The process is 
driven by upregulation of bone-forming transcription factors and proteins on VSMCs, such as 
Cbfa1 and bone morphogenetic protein 2, which control the expression of osteogenic proteins 
(osteocalcin, osteonectin, alkaline phosphatase, collagen type I, and bone sialoprotein). Exposure 
to high levels of calcium, phosphate, cytokines, and so on, along with the deficit of calcifica-
tion inhibitors (such as fetuin-A, matrix Gla protein, pyrophosphate) are required for the cells’ 
phenotypic switch [39]. The transformed cells deposit collagen and non-collagenous proteins in 
the arterial wall and incorporate calcium and phosphorus into matrix vesicles to initiate miner-
alization and crystal growth. The overall positive calcium and phosphorus balance from CKD 
patients supports both the cellular transformation and the generation of matrix vesicles [36].
3.2.2. Mineral metabolism abnormalities and vascular calcifications
Elevated calcium levels have long been implicated in the vascular calcifications observed in CKD 
patients. Early on, these patients are usually hypocalcemic as a result of calcitriol deficiency, 
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but treatment with calcium salts and vitamin D derivatives can induce a positive calcium 
balance or even overt hypercalcemia [30]. In this context, it is possible that in patients with 
advanced kidney disease, calcium that is absorbed from the gastrointestinal tract cannot be 
excreted by the failing kidneys nor can it be deposited in bones with altered turnover (either 
high or low turnover is detrimental) and is therefore deposited at extra-osseous sites, such 
as the vascular bed [5, 6]. Calcium changes in the external milieu have a direct effect on the 
nearby cells. Normally, VSMCs recognize these changes via the membrane such as calcium 
sensing receptor (CaR) and a G-protein-coupled receptor, which was shown to be downregu-
lated in calcified arteries from CKD patients, suggesting that calcium sensing is disrupted in 
these patients [6, 40]. In response to elevated extracellular calcium, VSMCs release calcium-
laden vesicles, as an attempt to prevent intracellular calcium overload. When the vesicles do 
not contain enough calcification inhibitors (as in CKD), this adaptive response in fact promotes 
extracellular matrix calcification by serving as a site of origin for propagated calcification [35].
Besides calcium, hyperphosphatemia that is so common in advanced CKD, has emerged as a 
major culprit of vascular calcifications [41]. Increased serum levels of phosphate induce osteo-
blastic transformation of VSMCs, while the decrease of phosphatemia reduces the expression 
of proteins responsible for active bone mineral deposition in vascular cells [15, 35]. As sug-
gested by in vitro studies, phenotypic transformation of VSMCs in response to hyperphos-
phatemia is mediated by Pit-1 (a type III sodium-phosphate cotransporter), which allow the 
influx of phosphate into VSMCs and predisposes the cells to undergo mineralization. It was 
observed that the first step of vascular calcification requires an increased uptake of calcium 
and phosphate by the VSMCs [42].
In addition to sodium-phosphate cotransport, alkaline phosphatase is necessary for the uptake 
of phosphorus into the cell and the subsequent induction of osteopontin. Moreover, VSMCs 
treated with pooled uremic sera from CKD patients also increased expression of osteopontin 
and mineral deposition, suggesting that uremic serum plays a role in vascular calcifications [43].
Clinical data also support the link between elevated phosphate and vascular calcifications. For 
example, in a population-based cohort without CKD, serum phosphate levels at the upper end 
of normal range were associated with aortic valve sclerosis and mitral annular calcification, inde-
pendent of PTH or calcium values [44]. Moreover, each 1 mg/dL increase in serum phosphate 
appears to predict higher risk for de novo coronary artery calcification (CAC) over time, with 
an impact similar to traditional cardiovascular risk factors, in relatively healthy subjects [45]. As 
in general population, phosphate serum concentration correlated with a greater risk of ectopic 
calcification in patients with moderate CKD (stage 3), as each 1 mg/dL increase in phosphatemia, 
even within normal laboratory ranges, was associated with a 21, 33, 25, and 62% higher preva-
lence of coronary and thoracic arteries, aortic and mitral valves calcifications, respectively [46].
Furthermore, in the presence of increased phosphate, even modest increases in calcium can 
substantially exacerbate calcification, by inducing nucleation of basic calcium-phosphate and, 
consequently, the growth of nascent vesicles that are released from both viable and apoptotic 
VSMCs [47]. The dominant role of phosphate is further supported by experimental studies 
which showed that dietary phosphate restriction in FGF23-null mice (an animal model charac-
terized by hyperphosphatemia, markedly elevated circulating calcitriol levels, extensive vas-
cular calcifications, and early mortality) yielded complete resolution of ectopic calcifications, a 
result which was not obtained with the vitamin D-deficient diet [48].
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The relationship between vitamin D and vascular calcification appears to follow a biphasic dose-
response curve, with adverse effects associated with very high and very low calcidiol levels [49]. At 
certain levels, vitamin D promotes bone formation by increasing the expression of critical matrix 
proteins in osteoblasts, leading to the incorporation of calcium into bone, thus taking it away 
from the vasculature. In addition, vitamin D may also prevent vascular calcifications through 
modulation of inflammatory responses [50]. Indeed, in dialysis patients, serum levels of calcidiol 
were inversely correlated with the extent of coronary calcifications [51], and clinical observations 
revealed that vitamin D receptor agonists were associated with decreased deposition of calcium, 
improved therapeutic outcomes, and survival benefits, independent of baseline levels of calcium, 
phosphate, parathyroid hormone, measured comorbidities, and kidney function [6, 15, 52].
However, vitamin D excess was associated with medial calcification and arterial stiffness [49]. 
Indeed, high doses of vitamin D may actually increase the risk of vascular calcification in 
CKD owing to its effects on increasing intestinal calcium and phosphate absorption, as well 
as the mobilization of these minerals from bone, leading to hypercalcemia and hyperphos-
phatemia, especially in patients already taking calcium-based phosphate binders [13, 50, 52]. 
Besides its indirect effects due to interactions with the other major factors involved in osteo-
blastic transformation of VSMCs, vitamin D appears to directly induce the phenotypic switch 
through the vitamin D receptors on VSMCs resulting in upregulation of proteins involved in 
calcium transport and mineralization such as osteopontin and osteocalcin [35, 53].
Taken together, these data suggest that excess calcitriol can promote vascular calcifications 
through several interrelated mechanisms, while moderate physiological or pharmacological 
doses are beneficial (by suppressing the expression of osteoblastic genes in VSMCs). Debate also 
exists concerning the potential differential effects and benefits of native vitamin D as compared 
to active vitamin D receptor agonists, with an assumption that early administration of nutri-
tional supplementation in CKD patients may prevent vascular calcification [54]. However, this 
remains to be proven by future research.
Secondary hyperparathyroidism may also be involved, indirectly, in the osteoblastic trans-
formation of VSMCs since its excessive action on bone resorption results in hypercalcemia 
and hyperphosphatemia [55]. Also, arterial hypertension which may result from persis-
tently increased parathyroid hormone (PTH), through the stimulation of renin-angiotensin-
aldosterone and sympathetic nervous systems, is another indirect pathway to endothelial 
dysfunction and arterial calcification [56]. Despite these pathogenetic links, the exact con-
tribution of PTH on vascular calcification is not known yet. In various clinical trials, thera-
pies directed to decrease PTH (parathyroidectomy and calcimimetics) provided discordant 
results on prevention or regression of vascular calcifications [57–59]. Moreover, both hyper-
parathyroidism (which induce high bone turnover and activation of osteoclasts with calcium 
and phosphorus release into the circulation) and suppressed PTH (which induce adynamic 
bone disease with low bone turnover and reduce uptake of calcium and phosphate into 
the bone) were associated with extensive arterial calcifications [60]. Consequently, it was 
hypothesized that parathyroid hormone does not exert a direct intervention in the pathogen-
esis of vascular calcification in CKD, so its exact role on this matter remains to be elucidated.
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The relationships of Fibroblast growth factor 23 (FGF23) and its receptor—Klotho—with 
calcifications were also investigated, but conflicting results were reported. Some authors 
found an association of increased FGF23 with carotid artery calcification in stages 3 and 4 
CKD patients [61], and with abdominal aortic calcifications in hemodialysis patients [62], 
while others observed contrary findings [63]. To date, it is not clear whether FGF23 can 
directly act on vascular cells to promote or inhibit matrix calcification. It is possible that the 
involvement of FGF23 in vascular calcification would be only indirect, through the related 
calcium-phosphate metabolism disturbances [64]. Alternatively, since FGF23 needs Klotho 
as mandatory co-receptor and Klotho (which controls the dedifferentiation of VSMCs by 
blocking the expression sodium-phosphate cotransporters) decreases from the early stages 
of CKD, the ability of FGF23 to interact with vascular cells is consequently altered [64, 65]. 
Despite the fact that experimental data are congruent to suggest that the effect of Klotho is 
protective against vascular calcifications, it still remains unknown whether or not Klotho 
is expressed in the vessel wall [64]. Thus, no definitive conclusions regarding the direct 
effects of FGF23 or Klotho on VSMCs functions can be drawn based on the current state 
of knowledge.
4. Clinical consequences of vascular calcifications in chronic kidney 
disease
Observational studies point to cardiovascular disease (CVD) as the leading cause of morbidity 
and mortality in CKD patients. The annual 2014 report of the United States Renal Data System 
estimates that, in patients with CKD, the prevalence of CVD is 69.8% compared to 34.8% in 
patients without renal disease, and these numbers increase with decline in kidney function 
[66]. In fact, the risk of any cardiovascular (CV) event seems to increase as estimated glomeru-
lar filtration rate (eGFR) decreases, ranging from a 43% increase in risk with an estimated GFR 
of 45–59 mL/min/1.73 m2 to a 600% increase in cardiovascular (CV) risk at an estimated GFR of 
less than 15 mL/min/1.73 m2 [67].
The burden of CVD in patients with CKD is, at least in part, accounted for by the presence of 
non-traditional risk factors, which are much more prevalent in this group. Among these, min-
eral metabolism abnormalities and vascular calcifications are commonly seen. For example, 
Russo et al. reported that 40% of patients with stage 3 CKD had coronary artery calcification 
compared with only 13% of the control subjects with no renal impairment [68]. Similar data 
were found in our own experience: a cross-sectional, unicentric study that enrolled 110 stable 
CKD patients not on renal replacement therapy, and 34 age- and gender-matched patients 
without CKD showed higher prevalence of coronary artery disease (defined as past myocardial 
infarction, angor pectoris associated with electrocardiographic or ultrasound indices, coronary 
angioplasty or bypass) in CKD (49% vs. 19%, p = 0.001). In addition, more CKD patients than 
Controls had valvular (38% vs. 17%, p = 0.02), and vascular calcification (carotid plaques 60% 
vs. 29%, p = 0.02 and abdominal aorta calcifications 54% vs. 26%, p = 0.003), irrespective of the 
CKD stage [69].




Clinical consequences of vascular calcifications in CKD include loss of arterial elasticity with 
resultant rise in arterial stiffness due to reduced compliance of large arteries, lower delivery of 
oxygen to the tissues, and endothelial dysfunction. Arterial stiffness represents the functional 
disturbance of vascular calcification and predominantly results from greater medial calcifica-
tion. The main consequence of arterial stiffness is increased pulse pressure, which contributes 
to left ventricular hypertrophy and impaired coronary perfusion by increasing ventricular 
afterload and reducing coronary blood flow during diastole [70]. In response to higher pres-
sure or flow, the arterial wall undergoes a remodeling process, which consists of either reor-
ganization of cellular and noncellular elements (eutrophic remodeling) or increased muscle 
mass (hypertrophic remodeling), both with significant impact on altered arterial function, 
that is, the reduced ability to buffer pressure, and pulsatile flow oscillations [71].
Aortic pulse wave velocity, an accurate and reproducible parameter of arterial stiffness and a 
marker of cardiovascular dysfunction, is linked to several other CV risk factors such as micro-
albuminuria and proteinuria, vascular calcifications, and left ventricular hypertrophy [72]. 
Wang and coworkers, in a study on 102 non-dialysis CKD patients, found an inverse rela-
tion between pulse wave velocity and estimated glomerular filtration rate, with a significant 
stepwise increase in pulse wave corresponding to the advance in CKD from stage 1 to 5 [73], 
suggesting that arterial stiffness increases with decreased kidney function. Contrary to this 
result, but in line with others which did not detect independent associations between eGFR 
and aortic stiffness [74, 75], in a cross-sectional, single-center study on 135 stable patients (79% 
with CKD), we found increased cardio-ankle vascular index (CAVI, a stiffness marker less 
influenced by blood pressure than pulse wave velocity) in 73% subjects, irrespective of chronic 
kidney disease presence and severity [76].
It is largely accepted that arterial stiffness is a powerful independent predictor of mortality 
and CVD in advanced CKD, as well as in general population [70].
More debatable is the influence of arterial stiffness on kidney function. In theory, besides the 
effects on myocardium, the decreased compliance of the large arteries would be followed by 
the transmission of cyclic blood flow from the aorta to peripheral microcirculations in various 
organs (including the kidneys) because its transformation in the physiological continuous 
capillary flow fails. Consequently, the protective autoregulatory mechanisms of the glomeru-
lar microcirculation are overpassed, and renal tissue becomes more vulnerable to the high 
blood pressure–related damage, favoring the decline in glomerular filtration [71]. Despite 
these pathogenetic explanations, clinical studies yielded conflicting results, as mentioned ear-
lier. The majority of large population-based studies (adult or elderly cohorts) seem to support 
an independent association of aortic stiffness (measured by carotid-femoral pulse wave veloc-
ity) with the risk of incident CKD, but not with the risk of CKD progression (even if, the latter 
is not a unanimously reported result) [71].
The presence of arterial stiffness in CKD patients is important also from the therapeutic point 
of view, since numerous trials investigating the efficacy of anti-hypertensive drugs in cardio-
logic cohorts showed significant differences among various therapeutic regimens with regard 
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to central hemodynamic parameters. Thus, it was found that calcium channel blockers but not 
beta-blockers, lower the central pulse pressure [77], so the presence of arterial stiffness could 
impact the choice of blood-pressure-lowering medication in CKD patients.
4.2. Atherosclerotic cardiovascular disease
Atherosclerotic lesions, which refer to intimal deposition of material with consecutive occlu-
sive consequences, are highly prevalent in CKD patients mainly due to traditional CV risk 
factors. Specific features of atherosclerosis in chronic kidney disease comprise a higher propor-
tion of calcified plaques among atherosclerotic plaques and a greater intervention of inflam-
matory stimuli than in general population [71]. Atherosclerosis represents one link between 
serum calcium and CVD with the content of coronary artery calcium emerging as a predictor 
of coronary heart disease [78]. Indeed, Budoff et al. showed a graded relationship between 
decreased kidney function in CKD patients and higher coronary artery calcification scores [79], 
connecting calcium and kidney function with the development of cardiovascular disease, in 
particular ischemic heart disease.
Even in the general population, lower level of kidney function was associated with increased 
5-year probability of atherosclerotic cardiovascular disease [80]. Many studies found an 
inverse association between the glomerular filtration rate and the risk of occurrence or pro-
gression of atherosclerosis. For example, a cross-sectional retrospective study on almost 450 
subjects with moderate to severe CKD (eGFR below 60 mL/min) and acute coronary syndrome 
suggested that estimated kidney function is an independent risk factor for atherosclerotic mul-
tivessel cardiovascular disease, as the decreased eGFR independently predicted a three-vessel 
coronary stenosis, with a magnitude dependent on the severity of renal impairment. The risk 
was seven times higher in patients with CKD stages 4–5 than in those with stage 1 CKD [81].
However, it should be mentioned that a significant proportion of cardiovascular death among 
CKD patients is not strictly related to atherosclerosis (i.e., it is not due to myocardial infarction, 
stroke, and heart failure), as the main event is sudden cardiac death which has a multifactorial 
causation [82].
Atherosclerotic lesions are usually accompanied by impairment of the endothelium. Endothelial 
function is often abnormal in CKD patients, who have diminished endothelium-dependent 
dilatation compared with controls and increased von Willebrand factor, regardless of the stage 
of renal disease and coexisting risk factors, suggesting that atherosclerosis may develop early 
in the progression of chronic kidney disease [83]. Besides common factors like age, hyper-
tension, diabetes, smoking, dyslipidemia, and atherosclerosis, endothelial dysfunction is also 
accounted for by retention of uremic toxins, fluid overload, anemia, phosphate load, increased 
FGF23, increased homocysteine, enhanced oxidative stress, impaired nitric oxide metabolism 
(accumulation of asymmetrical dimethyl l-arginine), accumulation of advanced glycation end 
products, proinflammatory cytokines, and impaired angiogenesis [84].
Vascular calcifications of the large arteries, like abdominal aorta (assessed by the lumbar aortic 
calcification score—ACS) is not only a predictor of the cardiovascular morbidity and mortal-
ity, but it could also provide an indirect estimation of the intrarenal vascular status, as we 
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found in a cross-sectional study that enrolled 77 stages 2–5 non-dialysis CKD patients, older 
than 50 years, and with known atherosclerotic disease. This study described increased aor-
tic calcification as eGFR declines and found that higher lumbar aortic calcification score was 
independently associated with lower ankle-brachial index and higher intima-media thickness, 
suggesting a relationship of abdominal calcifications with the extension of atherosclerosis in 
other territories [85]. In addition, the novel finding of the study was the ability of an aortic 
calcification score >5 to predict with 65% sensitivity and 68% specificity a pathologic (<0.7) 
renal resistive index (marker of intrarenal atherosclerotic lesions on Doppler ultrasound) [85].
4.3. Calcific uremic arteriolopathy
Previously referred to as calciphylaxis, this is another form of vascular calcification almost exclu-
sive to chronic kidney disease patients with kidney failure, although some cases were scarcely 
reported in non-CKD patients. Female gender, hyperphosphatemia, high alkaline phospha-
tase, and low serum albumin are among the risk factors of calcific uremic arteriolopathy [86]. 
It is typically found in end-stage kidney disease, obese, diabetic females, often associated with 
secondary hyperparathyroidism, hypercalcemia, hyperphosphatemia, malnutrition, chronic 
warfarin therapy, or hypercoagulability [87].
Calcific uremic arteriolopathy involves diffuse medial calcification of small- to medium-sized 
subcutaneous arteries and arterioles of up to 50-μm diameter, with intimal fibroprolifera-
tive occlusions that lead to necrosis. Histological abnormalities include intimal hyperplasia, 
inflammation, obliterative endovascular fibrosis, arteriolar medial calcification, and throm-
botic cutaneous ischemia. The result is dermal, subdermal, and adipose tissue necrosis with 
subsequent skin ulceration. Calciphylaxis occurs independent of osteogenic activity, when 
the physiological calcium phosphate solubility threshold exceeds 60 mg2/dL2 [13, 86].
Overt clinical signs include livedo reticularis advancing to patches of ischemic necrosis and 
painful skin ulcers, especially on the legs, thighs, abdomen, or breasts. Often, the initial pre-
senting complaint is a dull deep dermal pain with periods of neuritic-type dysesthesia associ-
ated with palpable subcutaneous nodules or dermal plaques, which evolve to livedo reticularis 
and then nonhealing ulcerations [7, 88]. These lesions predispose the patients to life-threaten-
ing skin necrosis or acral gangrene susceptible to supra-infectious complications. Dermal fat, 
lung, and mesentery are most commonly affected [7, 86].
Sepsis, which is also the main cause of death due to calcific uremic arteriolopathy, and ampu-
tation are among the severe morbidities associated with this obliterative disease.
5. Conclusions
In chronic kidney disease, even in non-dialysis stages, the prevalence of atherosclerotic lesions, 
vascular calcifications, and arterial stiffness are significantly higher as compared to patients 
of same-age without kidney damage. Because the interplay of multiple factors is responsible 
for the arterial disorders in CKD, the exact mechanism involved is still a matter of debate. 
Therefore, the best therapeutic approach to minimize the adverse impact of CKD-related 
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mineral and bone disorder on the patients’ outcome is not yet known and controversies exist 
especially regarding the influence of intestinal phosphate binders and vitamin D receptor acti-
vators on arterial calcifications.
Author details
Cristina Capusa1,2* and Daria Popescu1
*Address all correspondence to: ccalexandr@yahoo.com
1 “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
2 “Dr. Carol Davila” Teaching Hospital of Nephrology, Bucharest, Romania
References
[1] Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FDR. Global 
prevalence of chronic kidney disease: A systematic review and meta-analysis. PLoS One. 
2016;11(7):e0158765. DOI: 10.1371/journal.pone.0158765
[2] Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, 
Gansevoort RT. For the Chronic Kidney Disease Prognosis Consortium. Association of 
estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular 
mortality in general population cohorts: A collaborative meta-analysis. Lancet. 2010;375: 
2073-2081. DOI: 10.1016/S0140-6736(10)60674-5
[3] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 
clinical practice guideline for the evaluation and management of chronic kidney disease. 
Kidney International. 2013;(Suppl. 3):S1-S150. DOI: 10.1038/kisup.2012.73
[4] Kidney Disease Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO 
clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of 
chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney International. 
2009;(Suppl. 113):S1-S130. DOI: 10.1038/ki.2009.188
[5] Román-García P, Rodríguez-García M, Cabezas-Rodríguez I, López-Ongil S, Díaz-López B, 
Cannata-Andía JB. Vascular calcification in patients with chronic kidney disease: Types, 
clinical impact and pathogenesis. Medical Principles and Practice. 2011;20:203-211. DOI: 
10.1159/000323434
[6] Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: The killer of patients with 
chronic kidney disease. Journal of the American Society of Nephrology. 2009;20(7):1453-
1464. DOI: 10.1681/ASN.2008070692
[7] Thompson B, Towler DA. Arterial calcification and bone physiology: Role of the bone- 
vascular axis. Nature Reviews. Endocrinology. 2012;8:529-543. DOI: 10.1038/nrendo.2012.36
Mechanisms and Clinical Implications of Vascular Calcifications in Chronic Kidney Disease
http://dx.doi.org/10.5772/intechopen.72717
75
[8] Alfrey AC. The role of abnormal phosphorus metabolism in the progression of chronic 
kidney disease and metastatic calcification. Kidney International. 2004;66:S13-S17. DOI: 
10.1111/j.1523-1755.2004.09003.x
[9] Demer LL, Tintut Y. Vascular calcification pathobiology of a multifaceted disease. Cir-
culation. 2008;116:2938-2948. DOI: 10.1161/CIRCULATIONAHA.107.743161
[10] Amann K. Media calcification and intima calcification are distinct entities in chronic kid-
ney disease. Clinical Journal of the American Society of Nephrology. 2008;3(6):1599-1605. 
DOI: 10.2215/CJN.02120508
[11] Ronchetti I, Boraldi F, Annovi G, Cianciulli P, Quaglino D. Fibroblast involvement in soft 
connective tissue calcification. Frontiers in Genetics. 2013;4(22):1-16. DOI: 10.3389/fgene. 
2013.00022 eCollection 2013
[12] Hasegawa T, Yamamoto T, Tsuchiya E, Hongo H, Tsuboi K, Kudo A, Abe M, Yoshida T, 
Nagai T, Khadiza N, Yokoyama A, Oda K, Ozawa H, de Freitas PHL, Li M, Amizuka N. 
Ultrastructural and biochemical aspects of matrix vesicle-mediated mineralization. 
Japanese Dental Science Review. 2017;53(2):34-45. DOI: 10.1016/j.jdsr.2016.09.002
[13] Johnson RC, Leopold JA, Loscalzo J. Vascular calcification pathobiological mechanisms 
and clinical implications. Circulation Research. 2006;99:1044-1059. DOI: 10.1161/01.RES. 
0000249379.55535.21
[14] Duer MJ, Friscić T, Proudfoot D, Reid DG, Schoppet M, Shanahan CM, Skepper JN, 
Wise ER. Mineral surface in calcified plaque is like that of bone. Further evidence for 
regulated mineralization. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28: 
2030-2034. DOI: 10.1161/ATVBAHA.108.172387
[15] Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E. Pathogenesis of vascular calcifi-
cation in chronic kidney disease. Kidney International. 2005;68:429-436. DOI: 10.1111/ 
j.1523-1755.2005.00421.x
[16] Hruska KA, Mathew S, Lund RJ, Memon I, Saab G. The pathogenesis of vascular calcifica-
tion in the chronic kidney disease mineral bone disorder (CKD-MBD): The links between 
bone and the vasculature. Seminars in Nephrology. 2009;29(2):156-165. DOI: 10.1016/j.
semnephrol.2009.01.008
[17] Epstein M. Matrix Gla-Protein (MGP) not only inhibits calcification in large arteries 
but also may be renoprotective: Connecting the dots. eBioMedicine. 2016;4:16-17. DOI: 
10.1016/j.ebiom.2016.01.026
[18] Schurgers LJ, Cranenburg EC, Vermeer C. Matrix Gla-protein: The calcification inhibitor 
in need of vitamin K. Thrombosis and Haemostasis. 2008;100(4):593-603. DOI: 10.1160/
TH08-02-0087
[19] Van Campenhout A, Golledge J. Osteoprotegerin, vascular calcification and atheroscle-
rosis. Atherosclerosis. 2009;204(2):321-329. DOI: 10.1016/j.atherosclerosis.2008.09.033
[20] Liu W, Zhang X. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteo-
protegerin system in bone and other tissues. Molecular Medicine Reports. 2015;11:3212-
3218. DOI: 10.3892/mmr.2015.3152
Chronic Kidney Disease - from Pathophysiology to Clinical Improvements76
[21] Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Research & 
Therapy. 2007;9(1):S1-S7. DOI: 10.1186/ar2165
[22] Kaden JJ, Bickelhaupt S, Grobholz R, Haase KK, Sarikoç A, Kiliç R, Brueckmann M, Lang S, 
Zahn I, Vahl C, Hagl S, Dempfle CE, Borggrefe M. Receptor activator of nuclear factor κB 
ligand and osteoprotegerin regulate aortic valve calcification. Journal of Molecular Cell 
Biology. 2003;36(1):57-66. DOI: 10.1016/j.yjmcc.2003.09.015
[23] Villa-Bellosta R, Egido J. Phosphate, pyrophosphate, and vascular calcification: A question 
of balance. European Heart Journal. 2017;38:1801-1804. DOI: 10.1093/eurheartj/ehv605
[24] Narisawa S, Harmey D, Yadav MC, O'Neill CW, Hoylaerts MF, Millán JL. Novel inhibi-
tors of alkaline phosphatase suppress vascular smooth muscle cell calcification. Journal 
of Bone and Mineral Research. 2007;22(11):1700-1710. DOI: 10.1359/jbmr.070714
[25] Jahnen-Dechent W, Heiss A, Schäfer C, Ketteler M. Fetuin-A regulation of calcified 
matrix metabolism. Circulation Research. 2011;108:1494-1509. DOI: 10.1161/CIRCRE 
SAHA.110.234260
[26] Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten 
EW, Leunissen KM, Krediet RT, Dekker FW. For the Netherlands cooperative study 
on the adequacy of dialysis (NECOSAD). Association of serum fetuin-A levels with 
mortality in dialysis patients. Kidney International. 2007;72(2):202-207. DOI: 10.1038/
sj.ki.5002178
[27] Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM. Exploring the biology of vascu-
lar calcification in chronic kidney disease: What's circulating? Kidney International. 
2008;73(4):384-390. DOI: 10.1038/sj.ki.5002696
[28] Westenfeld R, Schafer C, Smeets R, Brandenburg VM, Floege J, Ketteler M, Jahnen-Dechent 
W. Fetuin-A (AHSG) prevents extraosseous calcification induced by uraemia and phos-
phate challenge in mice. Nephrology, Dialysis, Transplantation. 2007;22:1537-1546. DOI: 
10.1093/ndt/gfm094
[29] Shea CM, Edgar CM, Einhorn TA, Gerstenfeld LC. BMP treatment of C3H10T1/2 mes-
enchymal stem cells induces both chondrogenesis and osteogenesis. Journal of Cellular 
Biochemistry. 2003;90:1112-1127. DOI: 10.1002/jcb.10734
[30] Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in 
chronic kidney disease: Key roles for calcium and phosphate. Journal of the American 
Heart Association. 2011;109:697-711. DOI: 10.1161/CIRCRESAHA.110.234914
[31] Watson KE, Parhami F, Shin V, Demer LL. Fibronectin and collagen I matrixes pro-
mote calcification of vascular cells in vitro, whereas collagen IV matrix is inhibitory. 
Arteriosclerosis, Thrombosis, and Vascular Biology. 1998;18:1964-1971. DOI: 10.1161/01.
ATV.18.12.1964
[32] Kapustin AN, Shanahan CM. Osteocalcin: A novel vascular metabolic and osteoinduc-
tive factor? Arteriosclerosis, Thrombosis, and Vascular Biology. 2011;31:2169-2171. DOI: 
10.1161/ATVBAHA.111.233601
Mechanisms and Clinical Implications of Vascular Calcifications in Chronic Kidney Disease
http://dx.doi.org/10.5772/intechopen.72717
77
[33] Jono S, Peinado C, Giachelli CM. Phosphorylation of osteopontin is required for inhibi-
tion of vascular smooth muscle cell calcification. The Journal of Biological Chemistry. 
2000;275(26):20197-20203. DOI: 10.1074/jbc.M909174199
[34] Kahles F, Findeisen HM, Bruemmer D. Osteopontin: A novel regulator at the cross roads 
of inflammation, obesity and diabetes. Molecular Metabolism 2014;3(4):384-393. DOI: 
10.1016/j.molmet.2014.03.004
[35] Shroff RC, McNair R, Skepper JN, Figg N, Schurgers LJ, Deanfield J, Rees L, Shanahan 
CM. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and 
extracellular matrix calcification. Journal of the American Society of Nephrology. 2010;21(1): 
1103-1112. DOI: 10.1681/ASN.2009060640
[36] Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. Journal 
of the American Society of Nephrology. 2008;19(2):213-216. DOI: 10.1681/ASN.2007080854
[37] Lorenzen J, Krämer R, Kliem V, Bode-Boeger SM, Veldink H, Haller H, Fliser D, Kielstein JT. 
Circulating levels of osteopontin are closely related to glomerular filtration rate and car-
diovascular risk markers in patients with chronic kidney disease. European Journal of 
Clinical Investigation. 2010;40:294-300. DOI: 10.1111/j.1365-2362.2010.02271.x
[38] Parker BD, Ix JH, Cranenburg ECM, Vermeer C, Whooley MA, Schurgers LJ. Association 
of kidney function and uncarboxylated matrix Gla protein: Data from the Heart and Soul 
Study. Nephrology, Dialysis, Transplantation. 2009;24(7):2095-2101. DOI: 10.1093/ndt/
gfp024
[39] Montezano AC, Zimmerman D, Yusuf H, Burger D, Chignalia AZ, Wadhera V, van 
Leeuwen FN, Touyz RM. Vascular smooth muscle cell differentiation to an osteogenic 
phenotype involves TRPM7 modulation by magnesium. Hypertension. 2010;56:453-462. 
DOI: 10.1161/HYPERTENSIONAHA.110.152058
[40] Molostvov G, James S, Fletcher S, Bennett J, Lehnert H, Bland R, Zehnder D. Extracellular 
calcium-sensing receptor is functionally expressed in human artery. American Journal of 
Physiology. Renal Physiology. 2007;293(3):F946-F955. DOI: 10.1152/ajprenal.00474.2006
[41] Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Inter-
national. 2009;75(9):890-897. DOI: 10.1038/ki.2008.644
[42] Shroff R, Long DA, Shanahan CM. Mechanistic insights into vascular calcification in 
CKD. Journal of the American Society of Nephrology. 2013;24(2):179-189. DOI: 10.1681/
ASN.2011121191
[43] Chen NX, O'Neill KD, Duan D, Moe SM. Phosphorus and uremic serum up-regulate osteo-
pontin expression in vascular smooth muscle cells. Kidney International. 2002;62:1724-
1731. DOI: 10.1046/j.1523-1755.2002.00625.x
[44] Linefsky JP, O’Brien KD, Katz R, de Boer IH, Barasch E, Jenny NS, Siscovick DS, Kestenbaum 
B. Association of serum phosphate levels with aortic valve sclerosis and annular calcifica-
tion. Journal of the American College of Cardiology. 2011;58(3):291-297. DOI: 10.1016/j.
jacc.2010.11.073
Chronic Kidney Disease - from Pathophysiology to Clinical Improvements78
[45] Tuttle KR, Short RA. Longitudinal relationships among coronary artery calcification, serum 
phosphorus, and kidney function. Clinical Journal of the American Society of Nephrology. 
2009;4(12):1968-1973. DOI: 10.2215/CJN.01250209
[46] Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, Kestenbaum BR. 
Association of serum phosphate with vascular and valvular calcification in moderate 
CKD. Journal of the American Society of Nephrology. 2009;20:381-387. DOI: 10.1681/
ASN.2008040349
[47] Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-
Dechent W, Weissberg PL, Shanahan CM. Human vascular smooth muscle cells undergo 
vesicle-mediated calcification in response to changes in extracellular calcium and phos-
phate concentrations: A potential mechanism for accelerated vascular calcification in 
ESRD. Journal of the American Society of Nephrology. 2004;15(11):2857-2867. DOI: 
10.1097/01.ASN.0000141960.01035.28
[48] Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X, Quarles LD. Role of hyperphosphate-
mia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic 
growth factor 23 null mice. Journal of the American Society of Nephrology. 2007;18:2116-
2124. DOI: 10.1681/ASN.2006121385
[49] Tilman BD, Massy ZA. Role of vitamin D in vascular calcification: Bad guy or good guy? 
Nephrology, Dialysis, Transplantation. 2012;27:704-1707. DOI: 10.1093/ndt/gfs046
[50] Rodriguez M, Martinez-Moreno JM, Rodríguez-Ortiz ME, Muñoz-Castañeda JR, 
Almaden Y. Vitamin D and vascular calcification in chronic kidney disease. Kidney & 
Blood Pressure Research. 2011;34:261-268. DOI: 10.1159/000326903
[51] London GM, Guérin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Mëtivier F. 
Mineral metabolism and arterial functions in end-stage renal disease: Potential role 
of 25-hydroxyvitamin D deficiency. Journal of the American Society of Nephrology. 
2007;18(2):613-620. DOI: 10.1681/ASN.2006060573
[52] Cozzolino M, Ketteler M, Zehnder D. The vitamin D system: A crosstalk between the 
heart and kidney. European Journal of Heart Failure. 2010;12:1031-1041. DOI: 10.1093/
eurjhf/hfq112
[53] Hsu JJ, Tintut Y, Demer LL. Vitamin D and osteogenic differentiation in the artery 
wall. Clinical Journal of the American Society of Nephrology. 2008;3(5):1542-1547. DOI: 
10.2215/CJN.01220308
[54] Hou YC, Liu WC, Zheng CM, Zheng JQ, Yen TH, Role LKC. of vitamin D in uremic 
vascular calcification. BioMed Research International. 2017;2017:2803579. DOI: 10.1155/ 
2017/2803579
[55] Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: Pathogenesis, 
disease progression, and therapeutic options. Clinical Journal of the American Society of 
Nephrology. 2011;6:913-921. DOI: 10.2215/CJN.06040710
Mechanisms and Clinical Implications of Vascular Calcifications in Chronic Kidney Disease
http://dx.doi.org/10.5772/intechopen.72717
79
[56] Palit S, Kendrick J. Vascular calcification in chronic kidney disease: Role of disordered 
mineral metabolism. Current Pharmaceutical Design. 2014;20(37):5829-5833. DOI: 10.217
4/1381612820666140212194926
[57] Bleyer AJ, Burkart J, Piazza M, Russell G, Rohr M, Carr JJ. Changes in cardiovascular cal-
cification after parathyroidectomy in patients with ESRD. American Journal of Kidney 
Diseases. 2005;46:464-469. DOI: 10.1053/j.ajkd.2005.04.035
[58] Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, 
Lopez N, Downey G, Dehmel B, Floege J. The ADVANCE study: A randomized study 
to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification 
in patients on hemodialysis. Nephrology, Dialysis, Transplantation. 2011;26:1327-1339. 
DOI: 10.1093/ndt/gfq725
[59] Chertow GM, Block GA, Correa-Rotter R, et al. For EVOLVE trial investigators. Effect of 
cinacalcet on cardiovascular disease in patients undergoing dialysis. The New England 
Journal of Medicine. 2012;367:2482-2494. DOI: 10.1056/NEJMoa1205624
[60] Schlieper G, Schurgers L, Brandenburg V, Reutelingsperger C, Floege J. Vascular calci-
fication in chronic kidney disease: An update. Nephrology, Dialysis, Transplantation. 
2016;31(1):31-39. DOI: 10.1093/ndt/gfv111
[61] Nakayama M, Kaizu Y, Nagata M, Ura Y, Ikeda H, Shimamoto S, Kuma K. Fibroblast 
growth factor 23 is associated with carotid artery calcification in chronic kidney disease 
patients not undergoing dialysis: A cross-sectional study. BMC Nephrology. 2013;14:22. 
DOI: 10.1186/1471-2369-14-22
[62] Lee YT, Ng HY, Chiu TTY, Li LC, Pei SN, Kuo WH, Lee CT. Association of bone-derived 
biomarkers with vascular calcification in chronic hemodialysis patients. Clinica Chimica 
Acta. 2016;452:38-43. DOI: 10.1016/j.cca.2015.10.031
[63] Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, Chavkin NW, Rahman M, 
Wahl P, Amaral AP, Hamano T, Master SR, Nessel L, Chai B, Xie D, Kallem RR, Chen J, 
Lash JP, Kusek JW, Budoff MJ, Giachelli CM, Wolf M, for Chronic Renal Insufficiency 
Cohort Study Investigators. Fibroblast growth factor 23 is not associated with and does 
not induce arterial calcification. Kidney International. 2013;83(6):1159-1168. DOI: 10.1038/
ki.2013.3
[64] Yamada S, Giachelli CM. Vascular calcification in CKD-MBD: Roles for phosphate, 
FGF23, and Klotho. Bone. 2017;100:87-93. DOI: 10.1016/j.bone.2016.11.012
[65] MC H, Shi M, Zhang J, Quiñones H, Griffith C, Kuro-o M, Moe OW. Klotho deficiency 
causes vascular calcification in chronic kidney disease. Journal of the American Society 
of Nephrology. 2011;22(1):124-136. DOI: 10.1681/ASN.2009121311
[66] United States Renal Data System. 2014 USRDS annual data report: Epidemiology of kidney 
disease in the United States. Bethesda, MD: National Institutes of Health, National Institute 
of Diabetes and Digestive and Kidney Diseases; 2014. Available from https://www.usrds.
org/2014/download/V1_Ch_04_Cardiovascular-Disease_14.pdf [Accessed 2017.10.08]
Chronic Kidney Disease - from Pathophysiology to Clinical Improvements80
[67] Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the 
risks of death, cardiovascular events, and hospitalization. The New England Journal of 
Medicine. 2004;351:1296-1305. DOI: 10.1056/NEJMoa041031
[68] Russo D, Palmiero G, De Blasio AP, Balletta MM, Andreucci VE. Coronary artery cal-
cification in patients with CRF not undergoing dialysis. American Journal of Kidney 
Diseases. 2004;44(6):1024-1030. DOI: 10.1053/j.ajkd.2004.07.022
[69] Badulescu M, Capusa C, Stancu S, Blaga V, Ilyes A, Anghel C, Mircescu G. Cardiovascular 
abnormalities prevalence in non-dialysis chronic kidney disease patients. In: Abstracts 
to the XLVIIIth ERA-EDTA Congress, Praga, 23-26 June 2011. NDT Plus. 2011;4(suppl 2): 
4.s2.48. DOI: 10.1093/ndtplus/4.s2.48
[70] Toussaint ND, Kerr PG. Vascular calcification and arterial stiffness in chronic kidney 
disease: Implications and management. Nephrology (Carlton). 2007;12(5):500-509. DOI: 
10.1111/j.1440-1797.2007.00823.x
[71] Garnier AS, Briet M. Arterial stiffness and chronic kidney disease. Pulse. 2015;3:229-241. 
DOI: 10.1159/000443616
[72] Bellasi A, Ferramosca E, Ratti C. Arterial stiffness in chronic kidney disease: The usefulness 
of a marker of vascular damage. International Journal of Nephrology. 2011;2011:734832. 
DOI: 10.4061/2011/734832
[73] Wang MC, Tsai WC, Chen JY, Huang JJ. Stepwise increase in arterial stiffness correspond-
ing with the stages of chronic kidney disease. American Journal of Kidney Diseases. 
2005;45(3):2044-2053. DOI: 10.1053/j.ajkd.2004.11.011
[74] Briet M, Bozec E, Laurent S, Fassot C, London GM, Jacquot C, Froissart M, Houillier P, 
Boutouyrie P. Arterial stiffness and enlargement in mild-to-moderate chronic kidney 
disease. Kidney International. 2006;69:350-357. DOI: 10.1038/sj.ki.5000047
[75] Hermans MM, Henry R, Dekker JM, Kooman JP, Kostense PJ, Nijpels G, Heine RJ, 
Stehouwer CD. Estimated glomerular filtration rate and urinary albumin excretion are 
independently associated with greater arterial stiffness: The Hoorn Study. Journal of 
the American Society of Nephrology. 2007;18:1942-1952. DOI: 10.1681/ASN.2006111217
[76] Capusa C, Boitan B, Stefan G, Barsan L, Blaga V, Mircescu G. Age and malnutrition mark-
ers are predictors of arterial stiffness in adults with and without chronic kidney disease. 
In: Abstracts to the LIIth ERA-EDTA Congress, London, 28-31 May 2015. Nephrology 
Dialysis Transplantation. 2015;30(suppl 3):iii491. DOI: 10.3252/pso.eu.52era.2015
[77] Dudenbostel T, Glasser SP. Effects of antihypertensive drugs on arterial stiffness. 
Cardiology in Review. 2012;20(5):259-263. DOI: 10.1097/CRD.0b013e31825d0a44
[78] Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Szklo M, 
Bluemke DA, O'Leary DH, Tracy R, Watson K, Wong ND, Kronmal RA. Coronary calcium 
as a predictor of coronary events in four racial or ethnic groups. The New England Journal 
of Medicine. 2008;358(13):1336-1345. DOI: 10.1056/NEJMoa072100
Mechanisms and Clinical Implications of Vascular Calcifications in Chronic Kidney Disease
http://dx.doi.org/10.5772/intechopen.72717
81
[79] Budoff MJ, Rader DJ, Reilly MP, Mohler ER 3rd, Lash J, Yang W, Rosen L, Glenn M, 
Teal V, Feldman HI, for CRIC Study Investigators. Relationship of estimated GFR and 
coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) study. 
American Journal of Kidney Diseases. 2011;58(4):519-526. DOI: 10.1053/j.ajkd.2011.04.024
[80] Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, 
Levey AS, Sarnak MJ. Level of kidney function as a risk factor for atherosclerotic cardio-
vascular outcomes in the community. Journal of the American College of Cardiology. 
2003;41(1):47-55. DOI: 10.1016/S0735-1097(02)02663-3
[81] Olechnowicz-Tietz S, Gluba A, Paradowska A, Banach M, Rysz J. The risk of atheroscle-
rosis in patients with chronic kidney disease. International Urology and Nephrology. 
2013;45(6):1605-1612. DOI: 10.1007/s11255-013-0407-1
[82] Whitman IR, Feldman HI, Deo R. CKD and sudden cardiac death: Epidemiology, mech-
anisms, and therapeutic approaches. Journal of the American Society of Nephrology. 
2012;23(12):1929-1939. DOI: 10.1681/ASN.2012010037
[83] Thambyrajaha J, Landraya MJ, McGlynnb FJ, Jonesa HJ, Wheelerb DC, Townenda JN. 
Abnormalities of endothelial function in patients with predialysis renal failure. Heart. 
2000;83:205-209. DOI: 10.1136/heart.83.2.205
[84] Goligorsky MS. Pathogenesis of endothelial cell dysfunction in chronic kidney disease: A 
retrospective and what the future may hold. Kidney Research and Clinical Practice. 2015; 
34(2):76-82. DOI: 10.1016/j.krcp.2015.05.003
[85] Stefan G, Capusa C, Stancu S, Petrescu L, Nedelcu ED, Andreiana I, Mircescu G. Abdominal 
aortic calcification and renal resistive index in patients with chronic kidney disease: Is there 
a connection? Journal of Nephrology. 2014;27(2):173-179. DOI: 10.1007/s40620-013-0021-4
[86] Disthabanchong S. Vascular calcification in chronic kidney disease: Pathogenesis and clin-
ical implication. World Journal of Nephrology. 2012;1(2):43-53. DOI: 10.5527/wjn.v1.i2.43
[87] Schiffrin EL, Lipman M, Mann JFE. Chronic kidney disease: Effects on the cardiovascular 
system. Circulation. 2007;116(1):85-97. DOI: 10.1161/CIRCULATIONAHA.106.678342
[88] Sowers KM, Hayden MR. Calcific uremic arteriolopathy: Pathophysiology, reactive oxy-
gen species and therapeutic approaches. Oxidative Medicine and Cellular Longevity. 
2010;3(2):109-121. DOI: 10.4161/oxim.3.2.5
Chronic Kidney Disease - from Pathophysiology to Clinical Improvements82
